Amneal Pharmaceuticals (AMRX) Common Equity (2017 - 2026)

Amneal Pharmaceuticals' Common Equity history runs 10 years deep, the most recent figure standing at -$46.0 million for Q1 2026.

• In Q1 2026, Common Equity rose 65.18% year-over-year to -$46.0 million; the TTM figure through Mar 2026 stood at -$46.0 million (up 65.18% YoY), while the FY2025 annual figure was -$70.8 million, up 35.36% from the prior year.
• Common Equity was -$46.0 million for Q1 2026 at Amneal Pharmaceuticals, up from -$70.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $407.4 million in Q1 2022 to a low of -$132.0 million in Q1 2025.
• Historically, Common Equity has averaged $36.7 million across 5 years, with a median of -$46.0 million in 2026.
• The sharpest annual moves came in 2024 and 2026: Common Equity tumbled 647.26% in 2024, then soared 65.18% in 2026.
• A 5-year view of Common Equity shows it stood at $184.0 million in 2022, then sank by 89.12% to $20.0 million in 2023, then sank by 647.26% to -$109.5 million in 2024, then soared by 35.36% to -$70.8 million in 2025, then soared by 35.07% to -$46.0 million in 2026.
• The last three Common Equity figures came in at -$46.0 million (Q1 2026), -$70.8 million (Q4 2025), and -$109.5 million (Q3 2025), per Business Quant data.